Search PubMed⌕ Search

Biomedical subjects

C Nerl

Publications and source records attributed to C Nerl.

60 records · Page 4Linked to original sources
PubMed1983

Analysis of active and inactive complement C4 complotypes associated with subtypes of HLA-B17 in different racial groups.

HLA-A, B, and C antigens and the HLA-linked markers BF, C2, and C4 were determined in 1,799 unrelated Caucasians, 140 North American blacks, 140 Chinese, and 66 Japanese. One allele of the C4A locus (Rodgers), C4A*6, was found to code for a functionally inactive product in HLA-B17 (Bw57)-positive individuals, but for a functionally active product in HLA-B37- or HLA-B27-positive individuals. Further studies revealed that the functionally inactive C4A*6 gene product was found only in one subtype of HLA-B17, namely, 17.1 (Bw57, long). In addition, it was found that the frequency of the other subtype of HLA-B17, namely, 17.2(Bw58, short) varies greatly in different populations and that HLA-Bw58 is associated with either C4A*3,B*1 or C4A*3,B*Q0.

Alleles↗
PubMed1982

Factor B polymorphism in North American blacks: study of a new variant Bf F1.35.

A "new" variant of the factor B (Bf) system has been found in the serum of three individuals of a North American Black family. This variant migrates faster than Bf F1 and has been designated Bf F1.35 on account of the relative electrophoretic mobility using reference Bf typed sera. This new factor B variant (F1.35) was found to be functionally active using a specific hemolytic overlay technique and was inherited on an HLA-A28;Bw35;C4 A3,B1;C2C;DR3;GLO2 haplotype.

Black or African American↗
PubMed1982

The BF locus and HLA: rare alleles coding for functionally active and inactive factor-B products.

The genetic polymorphism of properdin factor B (BF) was studied in different populations. The rarer alleles, BF*F1 and BF*S1, occurred in Caucasians, were less frequent in North American blacks, and were not demonstrated in any of three Oriental populations studied. Two further alleles of BF, termed BF*FM and BF*SM, were found to exist in these populations. The BF*FM allele, which was found only in Caucasians, codes for a functionally inactive factor-B product, whereas the BF*SM allele (found in a single Chinese individual), like other alleles of BF, codes for a functionally active product. HLA haplotype analyses in individuals carrying the rarer alleles of BF revealed not only a strong association between BF*F1 and HLA-B18 and BF*S1 and HLA-Bw50 but an even stronger association between these BF alleles and alleles of the two C4 loci. BF*F1 occurred most frequently on a C4A*3,B*Q0 haplotype, whereas the BF*S1 allele was usually found on a C4A*2,B*1/B*Q0 haplotype. HLA haplotypes carrying the BF*FM and BF*SM alleles all carried the more common C*4A3,B*1 haplotype.

Alleles↗
PubMed1978

Association of low C2 and C4 serum levels with the HLA-DW2 allele in healthy individuals.

HLA typed unrelated healthy individuals (HLA-DW2 positive n = 64, and HLA-DW2 negative n = 72) were investigated for their C2 functional activity and C4 serum protein levels. For the C2 and C4 levels a bimodal distribution was found in HLA-DW2 positive and HLA-DW2 negative individuals. HLA-DW2 positive persons had a significantly higher incidence of low C2 and C4 serum levels. Our data support the concept that genes governing C2 as well as C4 serum levels are in linkage disequilibrium with the HLA-DW2 allele of the major histocompatibility complex.

Complement C2↗
PubMedDate not supplied

CHOP and COPBLAM chemotherapy for diffuse large cell non-Hodgkin's lymphomas: a retrospective comparison.

Between 1979 and 1985 61 consecutive patients with non-Hodgkin's lymphomas of unfavourable histology (mostly diffuse large cell lymphomas subclassified according to Kiel nomenclature) were treated in our departments by either the CHOP- (n = 34) or the COPBLAM-regimen (n = 27). A retrospective analysis revealed that prognostic variables, excluding primary central nervous system (CNS)-involvement (n = 5), were equally distributed between both groups. Remission rates were significantly higher in the COPBLAM treated patients as compared with the CHOP treated group (85 per cent versus 38 per cent CR, P = 0.001) even when cases with primary CNS-disease were excluded. The survival curve did not reach a plateau in CHOP treated cases, whereas 85 per cent of the COPBLAM treated group reached a plateau by 15 months. The mean observation time, however, was shorter in the COPBLAM treated group (37 versus 30 months, respectively). It is concluded that the COPBLAM regimen is superior to the CHOP-protocol in inducing complete responses in aggressive non-Hodgkin's lymphomas. Longer follow-ups are needed to definitely show if this corresponds to an increased proportion of 'cures'.

Adolescent↗